Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA4 | P22748 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | INMT | O95050 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | BRD2 | P25440 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17510318 | 0.88 | LMNA (0.33) | LMNA | |
| SCHEMBL3274371 | 0.88 | LMNA (0.33) | LMNA | |
| SCHEMBL4554691 | 0.78 | ALDH1A1 (0.34) | LMNAKMT2AGAAHPGDMCL1 | |
| SCHEMBL3420510 | 0.78 | LMNA (0.31) | LMNAKMT2AMCL1OPRK1ALDH1A1 | |
| SCHEMBL27751204 | 0.76 | LMNA (0.31) | LMNAHPGDMCL1OPRK1ALDH1A1 | |
| SCHEMBL1817592 | 0.76 | RIPK1 (0.33) | LMNAALDH1A1 | |
| SCHEMBL3805159 | 0.75 | HSD17B10 (0.42) | LMNAHPGDALDH1A1 | |
| SCHEMBL16056609 | 0.74 | — | — | |
| SCHEMBL3842022 | 0.72 | DPP4 (0.48) | ALDH1A1 | |
| SCHEMBL3029470 | 0.71 | HTR2C (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3897630-B1 | THIENOPYRIDINE INHIBITORS OF RIPK2 | CELGENE CORP (US) | 2024-01-10 | — | — | EP | disclosed |
| WO-2023141225-A1 | FUSED HETEROCYCLES AS 5-HT2A RECEPTOR AGONISTS | ONSERO THERAPEUTICS INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| EP-1592689-A4 | 3-AMINO-4-PHENYLBUTANOIC ACID DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO INC (US) | 2008-12-24 | — | — | EP | disclosed |
| US-7388019-B2 | 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK & CO., INC. (US) | 2008-06-17 | — | — | US | disclosed |
| US-20060074087-A1 | 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME LLC | 2006-04-06 | — | — | US | disclosed |
| EP-1592689-A2 | 3-AMINO-4-PHENYLBUTANOIC ACID DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | Merck & Co., Inc. (US) | 2005-11-09 | — | — | EP | disclosed |
| WO-2004069162-A2 | 3-AMINO-4-PHENYLBUTANOIC ACID DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO., INC. (US) | 2004-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074087-A1 | 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | DPP4, DPP3, DPP7 | CA1 2510/4885CA2 430/4885CA4 148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.